New Independent Data Further Demonstrates Clinical Utility of Daxor Corporation’s Blood Volume Analyzer (BVA-100) Over Surrogate Measurements
pharmaceutical investing Zogenix Announces Presentation of New Efficacy and Safety Data from its First Pivotal Phase 3 Clinical Trial
Cancer Genetics, Inc. to Receive $1.0 Million in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
pharmaceutical investing AMAG Pharmaceuticals Announces Closing of Exclusive Licensing Agreement for North American Rights to Rekynda™
Cancer Genetics, Inc. Announces Consolidation and Cost Reduction in Administrative and Operational Support Functions
SeeThruEquity Issues Update on BioSig Technologies Highlighting Companys Technology Being Featured in Mayo Clinic Research
E-Power Resources Inc. Announces Closing of Oversubscribed Hard Dollar and Flow-through Private Placements
